Insulin aspart

Insulin aspart is a recombinant analogue of human insulin. Following subcut aneous insulin injection (0.15 to 0.2 U/kg), significantly higher serum ins ulin concentrations an achieved in a shorter time with insulin aspart than with human insulin. The subsequent decline in serum insulin concentrations is also more rapid with insulin aspart. In healthy individuals undergoing euglycaemic glucose clamp testing, glucos e infusion rates were higher and reached maximum concentrations significant ly earlier after insulin aspart than after human insulin. Interindividual variability in pharmacodynamic and pharmacokinetic paramete rs with insulin aspart was generally less than that with human insulin, whe reas the intraindividual variability in these parameters was similar after each insulin. In patients with type 1 diabetes postprandial glucose excursions were less pronounced with insulin aspart than human insulin. Daytime glucose control was better and minimum glucose levels during the night were not as low with insulin aspart as with human insulin. In diabetic patients treated with insulin aspart there was generally a lowe r frequency of hypoglycaemic events than in patients treated with human ins ulin.